Secretory Leukocyte Protease Inhibitor Decreases Renal Ischemia Reperfusion Injury

GUERRIERI, N. AMBROSI, H. ROMEO, F. CICORA, F. TONIOLO, P. CICORA, C. INCARDONA, E. CHULUYAN

Poitier

Congreso; The First International Meeting On Ischemia Reperfusion Injuries in Transplantation; 2012

Ischemia reperfusion injury (IRI) remains one of the major problems in solid organ transplantation. The aim of this study was to evaluate the effect of recombinant human secretory leukocyte protease inhibitor (SLPI) in a model of rat IRI. Materials and methods: bilateral ischemic procedures were performed in male Sprague-Dawley rats of 200-300 g. Renal artery and vein were clamped for 40 minutes. After 24 hours of reperfusion, the animals were sacrificed. There were four experimental groups: i) Sham (no IRI); ii) Control (IRI + control buffer); iii) SLPI (IRI + SLPI); iv) dSLPI (IRI + SLPI without anti-serine protease activity). Animals were treated (250  g / kg ip) with control buffer, SLPI or dSLPI, 24 h pre-ischemia, during the ischemia and 6 hours post-ischemia. Results: Animals treated with SLPI or dSLPI showed lower levels of serum creatinine (control: 2.6 ± 1.0; SLPI: 1.2 ± 0.8; dSLPI 0.45 ± 0.41 mg/dl, p